- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
- Interventions
- Efgartigimod PH20 SC
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Inflammatory Demyelinating Neuropathy
- Interventions
- Alemtuzumab infusion
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Obesity, Immune Deficiency
- Interventions
- Institutional standard intravenous immune globulin treatment
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Somerville, New Jersey
- Conditions
- Antibody-mediated Rejection, NMO Spectrum Disorder, TTP, CIDP
- Interventions
- Not listed
- Lead sponsor
- Charles M Knudson
- Other
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2040
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Interventions
- TAK-881, HYQVIA, SC Investigational Needle Sets
- Biological · Device
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Palo Alto, California • New Haven, Connecticut + 13 more
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Immune globulin (human) 10% solution for intravenous administration
- Biological
- Lead sponsor
- Kedrion S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Lebanon, New Hampshire • El Paso, Texas
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Interventions
- Efgartigimod PH20 SC
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 21 more
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- H.P. Acthar® Gel
- Drug
- Lead sponsor
- Mamatha Pasnoor, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Los Angeles, California • Kansas City, Kansas + 2 more
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- empasiprubart, IVIg, empasiprubart-placebo, IVIg-placebo
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Rancho Mirage, California • Colorado Springs, Colorado + 9 more
- Conditions
- Polyneuropathy, Inflammatory Demyelinating, Chronic
- Interventions
- Not listed
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Swiftwater, Pennsylvania
- Conditions
- Pediatric Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Panzyga
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Orange, California • Louisville, Kentucky + 3 more
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Interventions
- HYQVIA
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Imeroprubart, Placebo
- Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Carlsbad, California • Orange, California + 27 more
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Interventions
- SAR445088 (IV), SAR445088 (SC)
- Drug
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Orange, California • Fairway, Kansas + 2 more
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Interventions
- HYQVIA, 0.25% albumin placebo solution with rHuPH20, IGIV GAMMAGARD LIQUID/KIOVIG, IGIV GAMUNEX®-C
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 14 more
- Conditions
- CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
- Interventions
- Gamunex-C, Xembify
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 7
- States / cities
- Rancho Mirage, California • Coral Springs, Florida • Miami, Florida + 4 more
- Conditions
- Peripheral Neuropathy, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Vasculitic Neuropathy (Disorder), Amyloidosis, Hereditary Neuropathy, Sarcoid Neuropathy
- Interventions
- Biopsy + Nerve Repair, Biopsy Only
- Device · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- riliprubart, Placebo, IVIg
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 31
- States / cities
- Homewood, Alabama • Scottsdale, Arizona • Los Angeles, California + 26 more
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Interventions
- TAK-411
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- La Jolla, California • San Francisco, California • Jacksonville, Florida + 10 more
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Interventions
- Rozanolixizumab
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Augusta, Georgia • Charlotte, North Carolina + 1 more
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Interventions
- Empasiprubart IV, Placebo IV
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Rancho Mirage, California • Colorado Springs, Colorado + 7 more
- Conditions
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Interventions
- Nipocalimab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 15
- States / cities
- Centennial, Colorado • Coral Springs, Florida • Maitland, Florida + 12 more
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Non-invasive vagus nerve stimulation (nVNS), Standard of care treatment
- Device · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Interventions
- IgPro10
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Los Angeles, California • Iowa City, Iowa + 6 more